CDKICyclin-Dependent Kinase Inhibitor
References in periodicals archive ?
5 35 62 Table 5: Comparison of Cyclins and CDKIs Between Phases in the Patient Groups Group Cyclin/CDKI G0/G1-S G0/G1-G2/M S-G2/M A P< 0.
CDKI p16 expression in the control group was significantly higher during the GO/G1 phase than during the S phase (P < 0.
CDKI p16 expression the in MM group was similar to that in the control group.
Distribution of cyclins and CDKIs during the G2/M phase was similar in the MM and control groups, whereas cyclin expression was similar during all 3 phases in the MM and CML groups.
In normal and hematologically malignant cells partial illumination of the cell cycle--and thus the etiopathology of malignancy--can only be determined via comparison of the quantified changes in the cyclical phases of cyclins and CDKIs in healthy and malignant proliferated cells.
Comparison of the cell cycle-regulating elements cyclin A, B, D, and E, and CDKIs p16 and p21 in the control group showed that cyclin D was expressed most frequently during the GO/G1 phase; the other cyclins were present in 33% of the cells, and the cyclin E level was very low.
Expression of cyclins A, B, D, and E, and CDKIs p21 and p16 during the GO/G1 and S phases were similar in the CML patients and controls (P > 0.
The present study used flow cytometry to analyze the expression of cyclins A, B, D, and E, and CDKIs p21 and p16 in patients with CML and MM, and controls.
This finding suggests another imbalance between cyclins and CDKIs that facilitates malignant cellular proliferation.